369 related articles for article (PubMed ID: 19434850)
21. Benefits of cocrystallisation in pharmaceutical materials science: an update.
Friščić T; Jones W
J Pharm Pharmacol; 2010 Nov; 62(11):1547-59. PubMed ID: 21039540
[TBL] [Abstract][Full Text] [Related]
22. Bulk, surface properties and water uptake mechanisms of salt/acid amorphous composite systems.
Bianco S; Tewes F; Tajber L; Caron V; Corrigan OI; Healy AM
Int J Pharm; 2013 Nov; 456(1):143-52. PubMed ID: 23948137
[TBL] [Abstract][Full Text] [Related]
23. Solid state amorphization of pharmaceuticals.
Willart JF; Descamps M
Mol Pharm; 2008; 5(6):905-20. PubMed ID: 18954076
[TBL] [Abstract][Full Text] [Related]
24. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
Blagden N; de Matas M; Gavan PT; York P
Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
[TBL] [Abstract][Full Text] [Related]
25. Glass transition and time-dependent crystallization behavior of dehydration bioprotectant sugars.
Schebor C; Mazzobre MF; Buera Mdel P
Carbohydr Res; 2010 Jan; 345(2):303-8. PubMed ID: 19962131
[TBL] [Abstract][Full Text] [Related]
26. Effect of counterion on the phase behaviour during lyophilization of indomethacin salt forms.
Kumar L; Baheti A; Mokashi A; Bansal AK
Eur J Pharm Sci; 2011 Sep; 44(1-2):136-41. PubMed ID: 21767640
[TBL] [Abstract][Full Text] [Related]
27. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
[TBL] [Abstract][Full Text] [Related]
28. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.
Rumondor AC; Marsac PJ; Stanford LA; Taylor LS
Mol Pharm; 2009; 6(5):1492-505. PubMed ID: 19634917
[TBL] [Abstract][Full Text] [Related]
29. An improved method to validate the relative humidity generation in sorption balances.
Wadsö L; Anderberg A; Slund I; Söderman O
Eur J Pharm Biopharm; 2009 May; 72(1):99-104. PubMed ID: 19022384
[TBL] [Abstract][Full Text] [Related]
30. Stabilization of amorphous paracetamol based systems using traditional and novel strategies.
Martínez LM; Videa M; López-Silva GA; de Los Reyes CA; Cruz-Angeles J; González N
Int J Pharm; 2014 Dec; 477(1-2):294-305. PubMed ID: 25447825
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of drug physical form during granulation, tabletting and storage.
Williams AC; Cooper VB; Thomas L; Griffith LJ; Petts CR; Booth SW
Int J Pharm; 2004 May; 275(1-2):29-39. PubMed ID: 15081136
[TBL] [Abstract][Full Text] [Related]
32. Saccharin as a salt former. Enhanced solubilities of saccharinates of active pharmaceutical ingredients.
Bhatt PM; Ravindra NV; Banerjee R; Desiraju GR
Chem Commun (Camb); 2005 Feb; (8):1073-5. PubMed ID: 15719120
[TBL] [Abstract][Full Text] [Related]
33. Determination of low levels of amorphous content in inhalation grade lactose by moisture sorption isotherms.
Vollenbroek J; Hebbink GA; Ziffels S; Steckel H
Int J Pharm; 2010 Aug; 395(1-2):62-70. PubMed ID: 20493937
[TBL] [Abstract][Full Text] [Related]
34. Preformulation evaluation of AZD1305, an oxabispidine intended for oral and intravenous treatment.
Sigfridsson K; Lundqvist R; Ohlson K
Drug Dev Ind Pharm; 2012 Jan; 38(1):19-31. PubMed ID: 21707325
[TBL] [Abstract][Full Text] [Related]
35. Measurement of low amounts of amorphous content in hydrophobic active pharmaceutical ingredients with dynamic organic vapor sorption.
Müller T; Schiewe J; Smal R; Weiler C; Wolkenhauer M; Steckel H
Eur J Pharm Biopharm; 2015 May; 92():102-11. PubMed ID: 25779351
[TBL] [Abstract][Full Text] [Related]
36. Application of a Salt Coformer in a Co-Amorphous Drug System Dramatically Enhances the Glass Transition Temperature: A Case Study of the Ternary System Carbamazepine, Citric Acid, and l-Arginine.
Ueda H; Wu W; Löbmann K; Grohganz H; Müllertz A; Rades T
Mol Pharm; 2018 May; 15(5):2036-2044. PubMed ID: 29630842
[TBL] [Abstract][Full Text] [Related]
37. Impact of counterion on the chemical stability of crystalline salts of procaine.
Guerrieri P; Jarring K; Taylor LS
J Pharm Sci; 2010 Sep; 99(9):3719-30. PubMed ID: 19967781
[TBL] [Abstract][Full Text] [Related]
38. Solid-state properties and crystallization behavior of PHA-739521 polymorphs.
Sun CC
Int J Pharm; 2006 Aug; 319(1-2):114-20. PubMed ID: 16720086
[TBL] [Abstract][Full Text] [Related]
39. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound.
Sigfridsson K; Forssén S; Holländer P; Skantze U; de Verdier J
Eur J Pharm Biopharm; 2007 Sep; 67(2):540-7. PubMed ID: 17383167
[TBL] [Abstract][Full Text] [Related]
40. The effect of temperature and moisture on the amorphous-to-crystalline transformation of stavudine.
Strydom S; Liebenberg W; Yu L; de Villiers M
Int J Pharm; 2009 Sep; 379(1):72-81. PubMed ID: 19540323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
